Découvrez nos professeurs et professeures!

Revenir au répertoire
Fiche précédente
Fiche suivante

Vincent Fradet

Médecin clinicien enseignant titulaire

Vincent Fradet
Vincent.Fradet@fmed.ulaval.ca
Centre de recherche sur le cancer
Centre de recherche du CHU de Québec - Université Laval
Nutrition, santé et société (NUTRISS)
Partager la fiche :

Contribution à la recherche

Thématiques de recherche de la Faculté de médecine

  • Bioinformatique / données massives (big data)
  • Oncologie
  • Santé cardiovasculaire, respiratoire et métabolisme
  • Santé des populations et pratiques optimales en santé

Projets de recherche en cours

  • Rôle du microbiote intestinal dans les cancers urologiques - CHU de Québec – Université Laval – CHUL - Développement de la recherche (FC), chercheur principal - 2025-04-01 au 2030-03-31
  • Institut sur la nutrition et les aliments fonctionnels (INAF) - Université Concordia, Institut national de recherche scientifique (INRS), Université du Québec à Rimouski, Fonds de recherche du Québec - Nature et technologies, Université McGill, Université Laval - Fonds internes, Merinov - Centre d'innovation de l'aquaculture et des pêches du Québec - Regroupements stratégiques NT, co-chercheur - 2024-04-01 au 2030-03-31
  • Etude des liens entre les habitudes de vie et les voies oncogéniques afin de développer des stratégies de diagnostic, de traitement et de prévention personnalisées contre les cancers urologiques - Fondation du CHU de Québec, chercheur principal - 2024-04-29 au 2028-03-31
  • Effets d'une supplémentation riche en oméga-3 (MAG-EPA) sur le micro-environnement tumoral prostatique - CHU de Québec – Université Laval – CHUL - Développement de la recherche (FC), chercheur principal - 2025-04-01 au 2028-03-31
  • PCa-19 GRePEC Étude de la relation entre habitude de vie, biomarqueurs et risque de cancer de la prostate - CHU de Québec – Université Laval – CHUL - Développement de la recherche (FC), chercheur principal - 2024-05-01 au 2027-05-01
  • Gut microbiota biomarkers to personalize treatment of bladder cancer - The W. Garfield Weston Foundation - Proof-of-Principle 2024: Microbial biomarkers of disease and therapeutic response, chercheur principal - 2024-12-01 au 2027-04-30
  • En route vers de nouvelles avenues thérapeutiques en cancer de la prostate - Fondation du CHU de Québec, chercheur principal - 2024-06-25 au 2026-10-01
  • Améliorer la réponse aux traitements en cancer de la vessie - Fondation du CHU de Québec, chercheur principal - 2024-06-25 au 2026-10-01
  • Repurposing bicalutamide to improve the response to immune checkpoint inhibition for treatment of advanced urothelial carcinoma - Société de recherche sur le cancer - UpCycle 2.1, co-chercheur - 2022-08-01 au 2026-07-31
  • Optimisation des procédures de recrutement et de collecte d’échantillons fécaux en oncologie - Fonds de recherche du Québec - Santé - Projet subsidiaire - Nouveaux Centres et Instituts de recherche - Subventions régulières (pour fins de gestion au VRRCI), chercheur principal - 2024-07-02 au 2025-07-31
  • Boosting the response to BCG immunotherapy: Harnessing the gut microbiota for bladder cancer treatment. - Association canadienne d'urologie, chercheur principal - 2024-06-06 au 2025-06-05
  • Identification des patrons alimentaires liés à l’incidence du cancer de la prostate - Fonds de recherche du Québec - Santé - Projet subsidiaire - Nouveaux Centres et Instituts de recherche - Subventions régulières (pour fins de gestion au VRRCI), chercheur principal - 2024-05-30 au 2025-05-31

Financements des 2 dernières années

  • Les habitudes de vie en cancer de la prostate au coeur d’une médecine personnalisée - Fonds de recherche du Québec - Santé - Chercheurs-boursiers cliniciens - Juniors 1 et 2, Seniors, chercheur principal - 2021-07-01 au 2024-06-30
  • Rôle des habitudes de vie sur le microbiote et la réponse clinique à l’immunothérapie en cancer de la vessie - Fonds de recherche du Québec - Santé - Projet subsidiaire - Nouveaux Centres et Instituts de recherche - Subventions régulières (pour fins de gestion au VRRCI), chercheur principal - 2023-04-20 au 2024-03-31
  • Institut sur la nutrition et les aliments fonctionnels (INAF) - Institut national de recherche scientifique (INRS), Fonds de recherche du Québec - Nature et technologies, Université Laval - Fonds internes, Université McGill, Université du Québec à Rimouski, Université de Sherbrooke - Regroupements stratégiques NT, co-chercheur - 2017-04-01 au 2024-03-31
  • Bactériophages et immunothérapie en cancer de la prostate - Fonds de recherche du Québec - Santé - Projet subsidiaire - Nouveaux Centres et Instituts de recherche - Subventions régulières (pour fins de gestion au VRRCI), chercheur principal - 2023-05-03 au 2024-03-31
  • Habitudes de vie, biomarqueurs et risque de cancer de la prostate - Fondation de l'Université Laval, chercheur principal - 2022-04-01 au 2024-03-31
  • En route towards prebiotic clinical trials for enhancement of immunotherapies in bladder and prostate cancers - The W. Garfield Weston Foundation - Transformational Research, chercheur principal - 2020-06-01 au 2023-05-31
  • What are my options? A feasibility study of a personalized primary prevention strategy for women and men at high risk of breast and prostate cancer - Instituts de recherche en santé du Canada, Fondation du cancer du sein du Québec, Société canadienne du cancer - Initiative SCC/IC-IRSC en prévention primaire du cancer, co-chercheur - 2022-01-15 au 2023-01-14

Publications

  • Development and Comparability of a Short Food-Frequency Questionnaire to Assess Diet in Prostate Cancer Patients: The Role of Androgen Deprivation Therapy in CArdiovascular Disease – A Longitudinal Prostate Cancer Study (RADICAL PC) Substudy, Mahshid Dehghan, Andrew Mente, Russell J de Souza, Vincent Fradet, Sumathy Rangarajan, Rajibul Mian, Bobby Shayegan, Sarah Karampatos, Jehonathan Pinthus, Darryl P Leong, Nevena Savija, Current Developments in Nutrition, 2021, 10.1093/cdn/nzab106
  • Green tea for ovarian cancer prevention and treatment: A systematic review of the in vitro, in vivo and epidemiological studies, Têtu, B., Bazinet, L., Fradet, V., Bairati, I., Labbé, D.P., Trudel, D., Gynecologic Oncology, 2012, 10.1016/j.ygyno.2012.04.048
  • Penile sonographic and clinical characteristics in men with peyronie's disease, Lue, T.F., Conti, S., Davis, C.B., Huang, Y.-C., Chi, T., Vittinghoff, E., Shindel, A.W., Fradet, V., Brant, W.O., Smith, J.F., Journal of Sexual Medicine, 2009, 10.1111/j.1743-6109.2009.01438.x
  • Pathological Outcomes of Candidates for Active Surveillance of Prostate Cancer, Carroll, P.R., Simko, J., Cowan, J.E., Fradet, V., Dall'Era, M., Conti, S.L., Journal of Urology, 2009, 10.1016/j.juro.2008.11.107
  • Nuclear factor-κB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer, Saad, F., Mes Masson, A.-M., Karakiewicz, P., Bégin, L.R., Lessard, L., Fradet, V., Clinical Cancer Research, 2004, 10.1158/1078-0432.CCR-04-0764
  • A delay in radical cystectomy of >3 months is not associated with a worse clinical outcome [2], Konety, B.R., Fradet, V., BJU International, 2008, 10.1111/j.1464-410X.2007.07394_2.x
  • Malignant mesothelioma of the tunica vaginalis testis: comprehensive review of literature and case report, Fradet, V., Levesque, J., Alesawi, A.M., Journal of Clinical Urology, 2015, 10.1177/2051415813511082
  • Prospective Assessment of Malnutrition in Urologic Patients, Stief, G.C., Walther, S., Speer, R., Fradet, V., Buchner, A., Rittler, P., Karl, A., Urology, 2009, 10.1016/j.urology.2008.12.037
  • Diagnostic performance of ultrasound for macroscopic hematuria in the era of multidetector computed tomography urography, Tang, A., Billiard, J.-S., Fradet, V., Lepanto, L., Rhéaume-Lanoie, J., Canadian Association of Radiologists Journal, 2014, 10.1016/j.carj.2013.08.001
  • Supplementary Figures 1-5 supporting the effects of MAG-EPA on prostate cancer from Omega-3 Eicosapentaenoic Acid Reduces Prostate Tumor Vascularity, Vincent Fradet, Alain Bergeron, André Marette, Pierre Julien, Arnaud Droit, Yves Fradet, Éric Fournier, Lisanne Beaudoin, Charles Joly Beauparlant, Karine Robitaille, Gabriel Lachance, Nikunj Gevariya, 2023, 10.1158/1541-7786.22526757.v1
  • Supplementary Figures 1-5 supporting the effects of MAG-EPA on prostate cancer from Omega-3 Eicosapentaenoic Acid Reduces Prostate Tumor Vascularity, Vincent Fradet, Alain Bergeron, André Marette, Pierre Julien, Arnaud Droit, Yves Fradet, Éric Fournier, Lisanne Beaudoin, Charles Joly Beauparlant, Karine Robitaille, Gabriel Lachance, Nikunj Gevariya, 2023, 10.1158/1541-7786.22526757
  • Assessing Cancer Risk on Novel 29 MHz Micro-Ultrasound Images of the Prostate: Creation of the Micro-Ultrasound Protocol for Prostate Risk Identification, Pavlovich, C.P., Wodlinger, B., McGrath, T., Hyndman, M.E., Fradet, V., Eure, G., Ghai, S., Journal of Urology, 2016, 10.1016/j.juro.2015.12.093
  • FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy, Pouliot, F., Bouchard, F., Rimac, G., Tiguert, R., Dujardin, T., Lacombe, L., Lemay, C., Fradet, Y., Caron, A., Fradet, V., Blouin, A.-C., Beauregard, J.-M., Cancer Imaging, 2015, 10.1186/s40644-015-0038-0
  • The impact of solitary and multiple positive surgical margins on hard clinical end points in 1712 adjuvant treatment-naive pT2-4 N0 radical prostatectomy patients, Fradet, Y., Tetu, B., Tiguert, R., Dujardin, T., Lacombe, L., Fradet, V., Mauermann, J., European Urology, 2013, 10.1016/j.eururo.2012.08.002
  • Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: Results from the Canadian Upper Tract Collaboration, Lacombe, L., Cagiannos, I., Drachenberg, D., Sheyegan, B., Saad, F., Bell, D., Lattouf, J.-B., So, A., Chin, J., Tanguay, S., Black, P., Kapoor, A., Izawa, J., Fairey, A., Jacobsen, N., Rendon, R., Kassouf, W., Mauermann, J., Fradet, V., Urologic Oncology: Seminars and Original Investigations, 2014, 10.1016/j.urolonc.2014.04.006
  • The 2002 AJCC pT2 substages confer no prognostic information on the rate of biochemical recurrence after radical prostatectomy, Karakiewicz, P.I., Huland, H., Graefen, M., Perrotte, P., McCormack, M., Erbersdobler, A., Haese, A., Eichelberg, C., Schlomm, T., Walz, J., Steuber, T., Fradet, V., Lebeau, T., Briganti, A., Chun, F.K.-H., European Urology, 2006, 10.1016/j.eururo.2005.12.009
  • IL-8 secretion in primary cultures of prostate cells is associated with prostate cancer aggressiveness, Fradet, V., Fradet, Y., Ayari, C., LaRue, H., Bergeron, A., Deschênes-Rompré, M.-P., Moreel, X., Neveu, B., Research and Reports in Urology, 2014, 10.2147/RRU.S58643
  • SRD5A polymorphisms and biochemical failure after radical prostatectomy, Lévesque, E., Guillemette, C., Girard, H., Douville, P., Bao, B.-Y., Huang, S.-P., Fradet, V., Fradet, Y., Lacombe, L., Nadeau, G., Bellemare, J., Audet-Walsh, E., European Urology, 2011, 10.1016/j.eururo.2011.06.020
  • New insights into gut microbiota–prostate cancer crosstalk, Vincent Fradet, Karine Robitaille, Yves Fradet, Alain Bergeron, Gabriel Lachance, Jalal Laaraj, Trends in Molecular Medicine, 2025, 10.1016/j.molmed.2025.03.015
  • Intermittent vs continuous androgen deprivation therapy for prostate cancer, Turgeon, A.F., Fradet, V., Vigneault, E., Shemilt, M., Bernier, L., Pilote, L., Zarychanski, R., Magnan, S., JAMA Oncology, 2015, 10.1001/jamaoncol.2015.2895
  • ω-3 Fatty acids, genetic variants in COX-2 and prostate cancer, Witte, J.S., Fradet, V., Reese, A.C., Journal of Nutrigenetics and Nutrigenomics, 2009, 10.1159/000235565
  • Urology residents on call: Investigating the workload and relevance of calls, Cloutier, J., Moore, K., Fradet, V., Blais, A.-S., Marceau-Grimard, M., Thériault, B., Canadian Urological Association Journal, 2018, 10.5489/cuaj.4333
  • The impact of germline genetic variations in hydroxysteroid (17-beta) dehydrogenases on prostate cancer outcomes after prostatectomy, Lévesque, É., Guillemette, C., Douville, P., Fradet, V., Fradet, Y., Lacombe, L., Bellemare, J., Audet-Walsh, É., European Urology, 2012, 10.1016/j.eururo.2011.12.021
  • Increased Prostate Cancer Glucose Metabolism Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8–10 Prostate Cancers Identifies Very High–risk Patients for Early Recurrence and Resistance to Castration, Pouliot, F., Beauregard, J.-M., Fradet, Y., Makao-Nguile, M., Fradet, V., Lacombe, L., Tiguert, R., Dujardin, T., Duchesnay, N., Blouin, A.-C., Buteau, F.-A., Bergeron, M., Lavallée, E., European Urology Focus, 2018, 10.1016/j.euf.2018.03.008
  • Comparison of digital image analysis and visual scoring of KI-67 in prostate cancer prognosis after prostatectomy, Fradet, V., Têtu, B., Fradet, Y., Lacombe, L., Caron, A., Léger, C., Nguilé-Makao, M., Hovington, H., Desmeules, P., Diagnostic Pathology, 2015, 10.1186/s13000-015-0294-0
  • The neutrophil-to-lymphocyte ratio (NLR) as a predictive marker of response to abiraterone acetate: A retrospective analysis of the COU302 study, P. Toren, V. Fradet, F. Pouliot, M. Nguile-Makao, T. Loubersac, European Urology Supplements, 2019, 10.1016/s1569-9056(19)30110-1
  • Urologist density and county-level urologic cancer mortality, Carroll, P.R., Ahmad, A.E., Fradet, V., Cooperberg, M.R., Odisho, A.Y., Journal of Clinical Oncology, 2010, 10.1200/JCO.2009.26.9597
  • Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low‐risk prostate cancer receiving 5α‐reductase inhibitors, Yves Fradet, Thierry Dujardin, Rabi Tiguert, Frédéric Pouliot, Louis Lacombe, Tal Ben‐Zvi, Alain Bergeron, André Caron, Caroline Léger, Jérome Lévesque, Michele Lodde, Molière Nguile‐Makao, Paul Toren, Vincent Fradet, BJU International, 2018, 10.1111/bju.14041
  • Is the Complication Rate of Radical Cystectomy Predictive of the Complication Rate of Other Urological Procedures?, Konety, B.R., Aaronson, D.S., Allareddy, V., Fradet, V., Journal of Urology, 2009, 10.1016/j.juro.2008.11.016
  • Prostate cancer managed with active surveillance: Role of anatomic MR imaging and MR spectroscopic imaging, Carroll, P.R., Shinohara, K., Coakley, F.V., Karl, A., Cowan, J.E., Kurhanewicz, J., Fradet, V., Radiology, 2010, 10.1148/radiol.10091147
  • Data from Omega-3 Eicosapentaenoic Acid Reduces Prostate Tumor Vascularity, Vincent Fradet, Alain Bergeron, André Marette, Pierre Julien, Arnaud Droit, Yves Fradet, Éric Fournier, Lisanne Beaudoin, Charles Joly Beauparlant, Karine Robitaille, Gabriel Lachance, Nikunj Gevariya, 2023, 10.1158/1541-7786.c.6545202.v1
  • Validation of the French-Canadian version of the Expanded Prostate Cancer Index Composite (EPIC) in a French-Canadian population, Fradet, V., Martin, A.-G., Foster, W., Després, P., Ivers, H., Savard, M.-H., Savard, J., Vigneault, É., Canadian Urological Association Journal, 2017, 10.5489/cuaj.4428
  • Renal cell carcinoma with thrombus extending to the hepatic veins or right atrium: Operative strategies based on 41 consecutive patients, Dagenais, F., Fradet, V., Pouliot, F., Lacombe, L., Gagné-Loranger, M., European Journal of Cardio-thoracic Surgery, 2016, 10.1093/ejcts/ezw023
  • Management of hepatic granulomatous tuberculosis complicating intravesical BCG for superficial bladder cancer, Paquin, J.-M., Côté, J., Perrotte, P., Gaudreau, C., Fradet, V., Journal of the Canadian Urological Association, 2007
  • Dietary omega-3 fatty acids, genetic variation and risk of breast and prostate cancers, Fradet, V., Pouliot, F., Mauermann, J., World Review of Nutrition and Dietetics, 2011, 10.1159/000327805
  • Data from Omega-3 Eicosapentaenoic Acid Reduces Prostate Tumor Vascularity, Vincent Fradet, Alain Bergeron, André Marette, Pierre Julien, Arnaud Droit, Yves Fradet, Éric Fournier, Lisanne Beaudoin, Charles Joly Beauparlant, Karine Robitaille, Gabriel Lachance, Nikunj Gevariya, 2023, 10.1158/1541-7786.c.6545202
  • An epidural abscess following transrectal ultrasound-guided biopsies of the prostate., Saad, F., Karakiewicz, P., Perrotte, P., McCormack, M., Fradet, V., The Canadian journal of urology, 2005
  • Re: Results from three municipal hospitals regarding radical cystectomy on elderly patients [1], Konety, B.R., Fradet, V., International Braz J Urol, 2008, 10.1590/S1677-55382008000100014
  • Reply from Authors re: Martin Spahn, Steven Joniau. Positive surgical margin at radical prostatectomy: Futile or surgeon-dependent predictor of prostate cancer death? Eur Urol 2013;64:26-8: Adjuvant versus salvage radiotherapy in patients with positive surgical margins at radical prostatectomy: That is the question, Fradet, Y., Fradet, V., Mauermann, J., European Urology, 2013, 10.1016/j.eururo.2012.10.047
  • Dietary omega-3 fatty acids, Cyclooxygenase-2 genetic variation, and aggressive prostate cancer risk, Witte, J.S., Casey, G., Cheng, L., Fradet, V., Clinical Cancer Research, 2009, 10.1158/1078-0432.CCR-08-2503
  • Preoperative nutritional factors and outcomes after radical cystectomy: A narrative review, Fradet, V., Lacombe, L., Fradet, Y., Robitaille, K., Lamarche, B., Ben-Zvi, T., Allaire, J., Canadian Urological Association Journal, 2017, 10.5489/cuaj.4471
  • Omega-3 Eicosapentaenoic Acid Reduces Prostate Tumor Vascularity, Vincent Fradet, Alain Bergeron, André Marette, Pierre Julien, Arnaud Droit, Yves Fradet, Éric Fournier, Lisanne Beaudoin, Charles Joly Beauparlant, Karine Robitaille, Gabriel Lachance, Nikunj Gevariya, Molecular Cancer Research, 2021, 10.1158/1541-7786.MCR-20-0316
  • Effects of concentrated long-chain omega-3 polyunsaturated fatty acid supplementation before radical prostatectomy on prostate cancer proliferation, inflammation, and quality of life: Study protocol for a phase IIb, randomized, double-blind, placebo-controlled trial, Fradet, V., Bairati, I., Savard, J., Julien, P., Duchesne, T., Pelletier, J.-F., Robitaille, K., Guertin, M.-H., BMC Cancer, 2018, 10.1186/s12885-017-3979-9
  • Effects of Concentrated Long-Chain Omega-3 Polyunsaturated Fatty Acid Supplementation on Quality of Life after Radical Prostatectomy: A Phase II Randomized Placebo-Controlled Trial (RCT-EPA), Vincent Fradet, Caroline Diorio, Josée Savard, Pierre Julien, Thierry Duchesne, Yves Caumartin, Thierry Dujardin, Rabi Tiguert, Michele Lodde, Paul Toren, Louis Lacombe, Yves Fradet, Roxane Tourigny, Jean-François Pelletier, Karine Robitaille, Hanane Moussa, Nutrients, 2023, 10.3390/nu15061369
  • Prospective Evaluation of Nutritional Factors to Predict the Risk of Complications for Patients Undergoing Radical Cystectomy: A Cohort Study, Fradet, V., Lacombe, L., Fradet, Y., Nguilé-Makao, M., Ben-Zvi, T., Léger, C., Allaire, J., Nutrition and Cancer, 2017, 10.1080/01635581.2017.1367941
  • Prostate cancer managed with active surveillance: Role of anatomic MR imaging and MR spectroscopic imaging, Carroll, P.R., Shinohara, K., Coakley, F.V., Karl, A., Cowan, J.E., Kurhanewicz, J., Fradet, V., International Braz J Urol, 2010, 10.1590/S1677-55382010000500019
  • High level of mature tumor-infiltrating dendritic cells predicts progression to muscle invasion in bladder cancer, Fradet, Y., Fradet, V., Têtu, B., Bergeron, A., Caron, A., Hovington, H., Larue, H., Ayari, C., Human Pathology, 2013, 10.1016/j.humpath.2013.01.014
  • Validation of the omega-3 fatty acid intake measured by a web-based food frequency questionnaire against omega-3 fatty acids in red blood cells in men with prostate cancer, Fradet, V., Lamarche, B., Julien, P., Caron, A., Léger, C., Labonté, M.-E., Moreel, X., Allaire, J., European Journal of Clinical Nutrition, 2015, 10.1038/ejcn.2015.7
  • Burden of illness of bone metastases in prostate cancer patients in Québec, Canada: A population-based analysis, Habib, M., Mitchell, D., Lelorier, J., Lauzon, V., Fradet, V., Perrault, L., Journal of the Canadian Urological Association, 2015, 10.5489/cuaj.2707
  • Geographic Distribution of Urologists Throughout the United States Using a County Level Approach, Carroll, P.R., Ahmad, A.E., Cooperberg, M.R., Fradet, V., Odisho, A.Y., Journal of Urology, 2009, 10.1016/j.juro.2008.10.034
  • Omega-3 Fatty Acids Survey in Men under Active Surveillance for Prostate Cancer: from Intake to Prostate Tissue Level, Fradet, V., Julien, P., Lamarche, B., Têtu, B., Desmeules, P., Diorio, C., Gevariya, N., Moreel, X., Pelletier, J.-F., Allaire, J., Guertin, M.-H., Robitaille, K., Nguile-Makao, M., Moussa, H., Nutrients, 2019, 10.3390/nu11071616
  • Poor agreement of prostate specific antigen doubling times calculated using ultrasensitive versus standard prostate specific antigen values: Important impact on risk assessment, Carroll, P.R., Davis, C.B., Whitson, J.M., Fradet, V., Reese, A.C., Journal of Urology, 2011, 10.1016/j.juro.2011.07.119
  • Omega‐3 fatty acids decrease prostate cancer progression associated with an anti‐tumor immune response in eugonadal and castrated mice, Vincent Fradet, Alain Bergeron, Yves Fradet, Pierre Julien, Anwar Alesawi, Lamoussa Diabaté, Valérie Picard, Karine Robitaille, Marjorie Besançon, Nikunj Gevariya, The Prostate, 2019, 10.1002/pros.23706
  • Use and duration of antibiotic prophylaxis and the rate of urinary tract infection after radical cystectomy for bladder cancer: Results of a multicentric series, Lodde, M., Toren, P., Fradet, Y., Lacombe, L., Lemire, F., Pycha, A., Comploj, E., Fradet, V., Fritsche, H.-M., Tandogdu, Z., Mayr, R., Ladurner, C., Haider, M., Urologic Oncology: Seminars and Original Investigations, 2019, 10.1016/j.urolonc.2019.01.017
  • Metabolic Imaging of Prostate Cancer Reveals Intrapatient Intermetastasis Response Heterogeneity to Systemic Therapy, Frédéric Pouliot, Yves Fradet, Vincent Fradet, Louis Lacombe, Molière Nguile Makao, Michelle Bergeron, Jean-Mathieu Beauregard, Fannie Morin, European Urology Focus, 2017, 10.1016/j.euf.2017.02.007
  • Prostatic and dietary omega-3 fatty acids and prostate cancer progression during active surveillance, Fradet, V., Têtu, B., Desmeules, P., Julien, P., Lamarche, B., Labonté, M.-È., Caron, A., Léger, C., Allaire, J., Moreel, X., Cancer Prevention Research, 2014, 10.1158/1940-6207.CAPR-13-0349
  • Phase II drug-metabolizing polymorphisms and smoking predict recurrence of nonâ€"muscle- invasive bladder cancer: A geneâ€"smoking interaction, Guillemette, C., Fradet, Y., Harvey, M., Nguile-Makao, M., Caron, A., Hovington, H., Bergeron, A., Larue, H., Pouliot, F., Levesque, E., Fradet, V., Lacombe, L., Cancer Prevention Research, 2016, 10.1158/1940-6207.CAPR-15-0069

Contribution à l'enseignement aux cycles supérieurs

Étudiant(e)s dirigé(e)s*

Depuis 2020/05
  • Lamoussa Diabaté - Doctorat - En cours
  • Xavier-Philippe Légaré - Maîtrise avec mémoire - En cours
  • Marine Boireau - Doctorat - En cours
  • Lucie Leclair - Doctorat - En cours
  • Clément Larose - Doctorat - En cours
  • Jalal Laaraj - Doctorat - En cours
  • Amenan Prisca Nadege Kone - Post-doctorat - En cours
  • Marie-Pier Filion - Maîtrise avec mémoire - En cours
  • Roxane Tourigny - Maîtrise avec mémoire - 2023/09

Encadrement d'étudiant(e)s

Direction de recherche dans les domaines suivants :

  • Biologie cellulaire et moléculaire
  • Épidémiologie
  • Sciences cliniques et biomédicales

En savoir plus sur les programmes

Disponibilité d'encadrement d'étudiant(e)s

Ce (cette) professeur(e) est présentement à la recherche d'étudiant(e)s.

Envoyer un courriel
*Les supervisions d’étudiant(e)s de 1er cycle en stage de recherche et de résident(e)s aux études médicales postdoctorales seront répertoriées ultérieurement.
Mettre à jour mon profil de professeur(e)